Pentoxifylline for Primary Biliary Cirrhosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01249092|
Recruitment Status : Completed
First Posted : November 29, 2010
Results First Posted : December 9, 2013
Last Update Posted : December 9, 2013
Primary biliary cirrhosis (PBC) is cholestatic liver disease characterized by progressive destruction of small bile ducts within the liver that can lead to end stage liver disease and all its complications.
Although ursodeoxycholic acid (UDCA) is associated with increased survival in many patients with PBC, there is absence of an adequate response to UDCA in a significant proportion of PBC patients.
Tumor necrosis factor alpha (TNF-alpha) is a cytokine that plays an important role in the pathogenesis of PBC. Other fibrosis biomarkers such as tissue metallo proteinase 1 (TIMP-1) are associated with progression of liver fibrosis in PBC. Pentoxifylline (PTX) is a methylxanthine derivative that inhibits pro-inflammatory cytokines and also has shown anti-fibrotic effects in serum of patients with PBC. Furthermore, PTX has well known clinical and safety profiles. The main hypothesis of this study is that therapy with pentoxifylline (PTX) will result in improvement of liver disease in PBC patients who are incomplete responders to UDCA.
The focus of this proposal is on the effectiveness of PTX in improving laboratory parameters of liver disease and levels of cytokines involved in the pathogenesis of the disease in patients with PBC.
|Condition or disease||Intervention/treatment||Phase|
|Primary Biliary Cirrhosis||Drug: Pentoxifylline||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Pilot Study of Pentoxifylline for the Treatment of Primary Biliary Cirrhosis|
|Study Start Date :||November 2010|
|Actual Primary Completion Date :||June 2012|
|Actual Study Completion Date :||March 2013|
Experimental: Pentoxifylline 400 mg TID
This study is an open label pilot with only one arm.
Patients will take 400mg of pentoxifylline three times daily for a total duration of 6 months.
- Change in Serum Alkaline Phosphatase Levels. [ Time Frame: 6 months ]Serum alkaline phosphatase levels at entry and at 6 months of therapy with PTX will be measured and compared.
- Change in Serum Concentration of Tissue Inhibitor Metalloproteinase 1 (TIMP-1) After PTX Therapy. [ Time Frame: 6 months ]Serum concentration of tissue inhibitor metalloproteinase 1 (TIMP-1), a fibrosis biomarker of interest, will be measured and the change in serum levels between entry and end of study will be calculated.
- Safety of Therapy in the Pilot Study of PTX Therapy in Patients With PBC Will be Assessed [ Time Frame: 6 months ]The number of participants that experienced any severe adverse events will be monitored and recorded.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01249092
|United States, Ohio|
|Cleveland, Ohio, United States, 44195|
|Principal Investigator:||Claudia O. Zein, MD, MSc||The Cleveland Clinic|